Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial.
Fiche publication
Date publication
avril 2021
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Martens P, Ferreira JP, Vincent J, Abreu P, Busselen M, Mullens W, Tang WWH, Böhm M, Pitt B, Zannad F, Rossignol P
Lien Pubmed
Résumé
Sodium changes are common in myocardial infarction (MI) complicated with left ventricular systolic dysfunction (LVSD) and/or heart failure (HF). Sodium handling is fine-tuned in the distal nephron, were eplerenone exhibits some of its pleotropic effects. Little is known about the effect of eplerenone on serum sodium and the prognostic relevance of sodium alterations in patients with MI complicated with LVSD and/or HF.
Mots clés
Electrolytes, Eplerenone, Heart failure, Hypernatremia, Hyponatremia, Myocardial infarction, Systolic dysfunction
Référence
Clin Res Cardiol. 2021 Apr 23;: